Kagocel 12mg 20 tablets

Form

tableti

Dosage mg

12

Pack

20

Composition of 1 tablet: Active substance: Kagocel (calculated on dry matter) - 12 mg. Excipients: Potato starch - 10 mg, Calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate - 91% to 95%, povidone (Kollidon 30) - 3.0% to 4.0%, crospovidone (Kollidon CL) - 3.0% to 4.0%) - up to a tablet mass of 100 mg. Description: Tablets are white to light brown in color, round, biconvex, with brown inclusions. For more information, see the blog: Kagocel - a systemic antiviral drug. Pharmacotherapeutic group: Antiviral agent. ATC code: [J05AX]. Pharmacological properties. Pharmacodynamics. The main mechanism of Kagocel® is its ability to induce interferon production. Kagocel® induces the formation of so-called late interferon in the human body, which is a mixture of α- and β-interferons, possessing high antiviral activity. Kagocel® induces interferon production in practically all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. After oral administration of one dose of Kagocel®, the interferon titer in blood serum reaches maximum values 48 hours later. The body's interferon response to Kagocel® administration is characterized by prolonged circulation of interferon in the bloodstream (up to 4-5 days). The dynamics of interferon accumulation in the intestines after oral administration of Kagocel® do not coincide with the dynamics of circulating interferon titers. Interferon production in blood serum reaches high values only 48 hours after administration of Kagocel®, while the maximum interferon production in the intestines is observed as early as 4 hours later. Kagocel® drug, when administered at therapeutic doses, is not toxic and does not accumulate in the body. The drug has no mutagenic or teratogenic properties, is not carcinogenic, and has no embryotoxic effects. The highest efficacy in treatment with Kagocel® is achieved when it is administered no later than the 4th day from the onset of acute infection. For prophylactic purposes, the drug can be used at any time, including immediately after contact with the infectious agent. Pharmacokinetics. 24 hours after administration, Kagocel® accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, and blood plasma. The low content of Kagocel® in the brain is explained by the drug's high molecular weight, which makes it difficult to penetrate the blood-brain barrier. In blood plasma, the drug is mainly in a bound form. With repeated daily administration of Kagocel®, the volume of distribution varies within wide limits in all examined organs. Drug accumulation is particularly pronounced in the spleen and lymph nodes. After oral administration, approximately 20% of the administered dose enters the general bloodstream. The absorbed drug circulates in the blood, mainly in a form bound to macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is approximately 16%. Excretion: The drug is excreted from the body mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted, including 90% through the intestines and 10% through the kidneys. The drug is not detected in exhaled air. Indications for use. Kagocel® is used in adults and children from 3 years of age as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections, as well as a therapeutic agent for herpes in adults. Contraindications: Pregnancy and lactation period; Age up to 3 years; Hypersensitivity to the components of the drug; Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Use during pregnancy and breastfeeding. Due to the lack of necessary clinical data, the use of the drug during pregnancy and breastfeeding is not recommended. Method of administration and dosage. Orally, regardless of food intake. For the treatment of influenza and other acute respiratory viral infections in adults, 2 tablets are prescribed 3 times a day for the first two days, and one tablet 3 times a day for the next two days. Total per course - 18 tablets, course duration - 4 days. Prevention of influenza and acute respiratory viral infections in adults is carried out in 7-day cycles: two days - 2 tablets once a day, 5-day break, then the cycle is repeated. Duration of prophylactic course - from one week to several months. For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. Total per course - 30 tablets, course duration - 5 days. For the treatment of influenza and acute respiratory viral infections in children aged 3 to 6 years, one tablet is prescribed twice a day for the first 2 days, and one tablet once a day for the next two days. Total per course - 6 tablets, course duration - 4 days. For the treatment of influenza and acute respiratory viral infections in children aged 6 years and older, one tablet is prescribed 3 times a day for the first 2 days, and one tablet twice a day for the next two days. Total per course - 10 tablets, course duration - 4 days. Prevention of influenza and acute respiratory viral infections in children from 3 years of age is carried out in 7-day cycles: two days - one tablet once a day, 5-day break, then the cycle is repeated. Duration of prophylactic course - from one week to several months. If there is no improvement after treatment, or symptoms worsen, or new symptoms appear, consult a doctor. Use the drug only according to the indications, method of administration, and dosage specified in the instructions. Side effects. Allergic reactions may develop. If any of the side effects listed in the instructions become severe, or if you notice any other side effects not listed in the instructions, inform your doctor. Overdose. In case of accidental overdose, it is recommended to drink plenty of fluids and induce vomiting. Interaction with other medicinal products. Kagocel® is well combined with other antiviral drugs, immunomodulators, and antibiotics (additive effect). Special instructions. To achieve a therapeutic effect, the drug should be started no later than the fourth day from the onset of the disease. Effect on the ability to drive vehicles and operate machinery. The effect of the drug on the ability to drive vehicles and operate machinery has not been studied. Dosage form. 12 mg tablets. 10 tablets in a contour cell package made of PVC/PVDC (polyvinyl chloride/polyvinylidene chloride) film and aluminum foil with a heat-sealed coating. 1, 2, or 3 contour cell packages are placed in a cardboard box with instructions for use. Shelf life. 4 years. Do not use the drug after the expiry date indicated on the packaging. Storage conditions. Store in a dark place at a temperature not exceeding 25°C. Keep out of reach of children. Dispensing category: Pharmaceutical product group III, available without a prescription.